A by-product from Utah-based Intermountain Well being has raised $10 million to carry longitudinal organic and medical knowledge to biopharmaceutical corporations. 

End result Bio says it maintains unique rights to a bodily library and cloud-based knowledge lake masking over 40 years of de-identified affected person digital well being information and biospecimen knowledge. This intensive knowledge lake can allow biopharmaceutical corporations to achieve insights important to facilitating diagnostic and therapeutic growth. 

The corporate notes that it will possibly take over a decade and billions of {dollars} to acquire regulatory approval for remedies or diagnostic instruments. The issue begins with having access to longitudinal organic and medical affected person knowledge, which might take life sciences and biotech corporations months to gather and course of.   

With a constantly rising library of over 5 million de-identified affected person samples and medical knowledge spanning many years, End result Bio can provide speedy entry to retrospective affected person knowledge and quicker entry to 1000’s of potential sufferers for research.

The $10 million funding is from Merck World Well being Innovation Fund and Amgen Ventures. 

“With help from our traders, End result Bio is elevating the bar for healthcare innovation,” mentioned Lincoln Nadauld, M.D., Ph.D., president and CEO of End result Bio, in an announcement. He was beforehand vp, chief of precision well being & teachers at Intermountain. 

“On prime of our current longitudinal affected person knowledge, we’re including over 300,000 biospecimens to our knowledge lake annually,” Nadauld added. “Due to this, we’ve the power to rapidly determine distinctive affected person cohorts from our huge knowledge lake that may pace up important analysis, resulting in novel discoveries..”

Along with rushing up affected person recruitment, the brand new firm mentioned the platform presents fast question capabilities throughout genomic, organic, medical, and claims knowledge, which has already supported analysis on every little thing from population-wide genetic research to drug discovery.

“End result’s Intelligence Platform offers collaborators with entry to uniquely wealthy de-identified medical datasets,” mentioned David M. Rubin, Ph.D., managing director at Merck World Well being Innovation Fund (GHIF), in an announcement. “GHIF seems to be ahead to working with the gifted and skilled End result administration workforce to harness the ability of precision medication to enhance outcomes for sufferers.”